<DOC>
	<DOCNO>NCT01921972</DOCNO>
	<brief_summary>This national multicenter , double-blind , randomize , parallel-group trial 12 month duration . Following 4 week wash-out period , subject randomize one 2 treatment group : ( 1 ) galantamine CR 24 mg/day dose-titration twelve week [ maintenance phase week 9 ] , ( 2 ) combination galantamine CR 24 mg/day plus memantine 10 mg b.i.d . dose titration sixteen week ( 12 week galantamine [ maintenance phase week 9 ] , additional 4 week memantine ) .</brief_summary>
	<brief_title>The Efficacy Combination Regimen Patients With Mild Moderate Probable Alzheimer 's Disease</brief_title>
	<detailed_description>Based 1. establish efficacy , galantamine memantine subject Alzheimer 's disease , 2. galantamine 's dual mode action cholinesterase inhibitor allosteric modulator nicotinic acetylcholine receptor ( nAChR ) effect might lead enhanced neurotransmission neuronal population , i.e. , glutamatergic GABAergic , 3. memantine 's neuroprotective property , demonstrate several experimental system , yet clinical set primary hypothesis formulate treatment combination galantamine plus memantine , may exert additional effect level neurotransmitter modulation , reduce memory/cognitive problem AD patient . The effect combination therapy compare galantamine effect alone . As secondary hypothesis , propose combination treatment galantamine plus memantine could conceivably slow disease progression and/or delay progression dementia probable AD . It reasonable assume effect clearer combination therapy ( galantamine , memantine ) cholinesterase inhibitor alone evaluate long-term clinical trial ( rivastigmine , donepezil , galantamine ) . To corroborate potential disease modify effect reliably separate purely symptomatic effect , disease progress track clinical measure ( CDR rating ) , also use volumetric MRI technique . Fox et al . develop sensitive method follow change overall brain volume time . In 'normal ' age 0.2 % /year ( SD 0.3 % ) change brain volume document , whereas AD , change 2.8 % /year ( SD 1 % ) measure . People 'at risk ' develop AD show change 1.5 % /year . Recently establish rate hippocampal atrophy correlate change clinical status ageing ( 'conversion ' ) AD . Overall , brain atrophy MRI delineate hippocampal volume memory decline seem clearly link . The project prospectively investigate validity investigation hippocampal volume assess therapeutic effect AD . MR-proton-spectroscopy provide consistent evidence neuronal marker Nacetylaspartat ( NAA ) reduce AD , whereas role myo-inositol , choline creatine less clear . NAA think present exclusively neuron gray matter axonal process white matter glial cell . NAA signal loss suggest neuronal loss observe gray matter loss damage axonal structure observe white matter . A correlation NAA decrease tissue sample patient AD number senile plaque neurofibrillary tangle report . Recent result indicate severity dementia patient AD positively correlate decrease NAA/Cr parietal cortex temporal lobe . These data consistent observation amount synaptic loss dominant indicator dementia AD . The cognitive decline patient AD may link neuronal loss dysfunction preferentially temporoparietal association cortex . This project prospectively investigate validity spectroscopic abnormality assess therapeutic effect AD . The primary objective trial establish hypothesis combination galantamine plus memantine improves memory/cognitive performance large extent galantamine monotherapy AD subject one year double-blind treatment . Memory/cognitive performance assess ADAS-cog/11 . The confirmatory statistical assessment hypothesis base change ADAS-cog/11 baseline end treatment period . Additional endpoint variable assess exploratory manner parallel ADAS-cog : - Preservation functionality assess use ADCS-ADL/AD scale . - Global rating dementia assess use CDR rating instrument . - Neuropsychiatric symptom assess use NPI rating instrument . - Resource utilization assess use RUD rating instrument . - Caregiver burden assess use burden interview ( BI ) . - Safety adverse event report , laboratory parameter , vital sign , physical examination ECG The secondary hypothesis state combination therapy galantamine plus memantine effective galantamine alone delay clinical progression dementia population observation period one year . Global severity dementia assess CDR scale . Supplementary endpoint criterion hypothesis : - Reduction rate serial MRI determine brain ( hippocampal ) atrophy MRS-based parameter . - Safety adverse event report , laboratory parameter , vital sign , physical examination ECG . Further analysis sub-groups ( e.g. , determine biological variable ) biological outcome measure investigate diagnostic module respect measure plan .</detailed_description>
	<mesh_term>Alzheimer Disease</mesh_term>
	<mesh_term>Galantamine</mesh_term>
	<mesh_term>Memantine</mesh_term>
	<criteria>1 . Willingness participate , indicate write informed consent patient . The competence participate patient assess physician involved trial . 2 . Male postmenopausal female outpatient . 3 . Age &gt; 50 year time randomization . 4 . Diagnosis probable Alzheimer 's Disease ( accord NINCDSADRDA criterion ) . 5 . Clinical psychometric rating cutoff score ( valid randomisation ) : MMSE range 15 26 point . 6 . MRI brain scan old 12 month ( randomization ) compatible diagnosis Alzheimer 's Disease . ( The MRI brain scan must repeat old 12 month clinically indicate ) . 7 . Patient ambulatory adequate vision hearing ability allow neuropsychological testing . 8 . Patient knowledgeable , cooperative , reliable caregiver/informant willing follow study procedure indicate write informed consent . 1 . Dementia type AD : 1. vascular dementia HIS Score ( modify acc . Rosen ) &gt; 5 evidence VD acc . NINCDSAIREN criterion . 2. depressive pseudodementia define acc . DSMIV criterion major depression . 3. nonAD dementia . 2 . Significant neurological disease AD , cerebral tumor , Huntington 's disease , Parkinson 's disease , normal pressure hydrocephalus , subdural hematoma , mental retardation , history brain surgery serious head trauma residual deficit . 3 . Diagnosis psychosis ( require hospitalization antipsychotic therapy two week ) within past 10 year associate AD diagnosis alcoholism drug dependence within past 10 year . 4 . History epileptic seizure patient receive antiepileptic drug . 5 . Abnormal laboratory test result consider clinically relevant dementia : e.g. , electrolyte change , folate deficiency , vitamin B12 deficiency , pathological thyroid function ( T3 TSH level ) , positive syphilis serology . 6 . Patient , opinion investigator , suffer acute poorly control illness , : 1 . Presently uncontrolled hypertension ( &gt; 180 mmHg systolic &gt; 100 mmHg diastolic ) . 2 . Myocardial infarction within last six month . 3 . Patient uncompensated congestive heart failure ( NYHA Class III IV ) 4 . Severe renal , hepatic gastrointestinal disease , could alter absorption , metabolism excretion trial drug . 5 . Serum creatinine &gt; 130 Î¼mol/l 1.5 mg/dl , transaminase ( ALAT , ASAT ) GGT &gt; twice upper limit normal range . 6 . Uncontrolled diabetes entry doubleblind phase research project ( fast blood glucose &gt; 10.0 mmol/l 180 mg/dl repeat test ) patient require insulin treatment . 7 . Patient take inadmissible medication , : Any investigational drug . Anticonvulsants ( incl . barbiturate ) . AntiParkinson agent . Dopaminergic agent . Amantadine . Antimuscarinic agent ( i. e. , anticholinergic ) . Selegiline , MAOI . 8 . Any condition precludes cooperation test investigation study ( e.g. , see hearing loss , relevant confusion agitation , musculoskeletal disorder , contraindication magnetic resonance imaging , i.e. , presence pacemaker , metallic implant high risk area , presence metallic material high risk area , history claustrophobia . Hip implant contraindicate ) . 9 . Patient participate investigational clinical trial last 2 month .</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2013</verification_date>
	<keyword>AD , Dementia</keyword>
</DOC>